2 July 2026 - ** Deutsche Bank upgrades Bayer BAYGn.DE to "buy" from "hold," saying the recent Supreme Court ruling helps limit the group's liability related to glyphosate, the active ingredient in Roundup

** Last week U.S. Supreme Court ruled in favour of the company's efforts to curb state-level lawsuits alleging its Roundup weedkiller causes cancer

** The broker says the ruling makes the class settlement considerably more likely to hold and "should effectively cap the glyphosate exposure within existing provisions"

** With the major obstacle removed, the brokerage expects market focus to shift toward the fundamentals and a "compelling growth story" in Bayer's Crop Science and Pharmaceuticals divisions

** DB raises PT by 33% to €60, expecting mid-term portfolio optionality to unlock substantial value for the business

** The stock trades at a 2027 enterprise value to EBITDA ratio of 7.6x, which is materially below agriculture and healthcare peers, it also points out

** The stock has gained 32.4% YTD